$name
Engineered for growth
REGRANEX Gel is the only FDA-approved PDGF for the treatment of diabetic neuropathic ulcers, formulated to act as a first-line treatment following effective ulcer care.
The prevalence of diabetes is rising, with an estimated 15% of patients likely to experience a diabetic foot ulcer (DFU).1-3 85% of diabetes-related lower extremity amputations are preceded by a DFU4, yet it is estimated that 85% of those amputations can be prevented.3
Product Features
Application
Three-step application process – prepare, apply and cover.1
Designed for a flexible, once-daily application schedule as part of effective wound care and assessment, to be applied by either the clinician, caregiver or patient.
Note: Always remind patients to refrigerate REGRANEX Gel.
Evidence and Case Studies
Medical Education
No results.
No results.
Citations
Title
Text